

STEERING COMMITTEE

Robert Horsburgh  
Carole Mitnick  
Frank Cobelens  
Grania Brigden  
Erica Lessem  
Martin Grobusch  
Christoph Lange  
Ignacio Monedero  
Mark Harrington  
Salmaan Keshavjee  
Stefan Goldberg  
Salim Hamid  
Margareth Dalcolmo

## Strategic Goals and Objectives for 2015-2020

*The RESIST-TB Strategic Goals and Objectives for 2015-2020 are the result of a strategic planning process, culminating in a meeting held in Barcelona on October 29<sup>th</sup>, 2014. This meeting was attended by Steering Committee Members Carole Mitnick, Bob Horsburgh, Salim Hamid, Christian Lienhardt, Frank Cobelens, Salmaan Keshavjee, Grania Brigden, and RESIST-TB Staff Member Carly Rodriguez.*

### Goal I. Accelerate uptake of effective, scalable regimens for MDR-TB treatment

Objective 1: Facilitate and promote field trials of regimens with new agents

Objective 2: Develop new approaches to demonstrating effectiveness of potential MDR-TB treatment regimens utilizing Phase 2 and observational cohort data

Objective 3: Promote dialogue with regulatory agencies regarding new trial designs to enable timely approval of scalable regimens.

Objective 4: Provide information for clinicians/programs on how to use these scalable regimens

Objective 5: Collect data documenting success in getting new regimens into programmatic use

### Goal II. Advocate for clinical trials of preventive therapy for MDR-TB

Objective 1: Facilitate and promote observational cohort designs, pilot trials and full trials to address MDR-TB preventive therapy

Objective 2: Review animal model data supporting use of new agents for preventive therapy

### Goal III. Optimize communication between stakeholders in the MDR-TB community

Objective 1: Advance dialogue about strategies for accelerating MDR-TB treatment roll-out

Objective 2: Identify opportunities for increasing communication between stakeholders

Objective 3: Maintain role as independent broker on MDR-TB issues